Our In Vivo Pharmacology Disease Models provide an essential platform for evaluating novel therapies in oncology and immuno-oncology research. These models enable pharmaceutical and biotech companies to generate predictive insights before clinical trials, accelerating drug development and enhancing treatment strategies.
Cell Line Derived Xenograft (CDX) Models
CDX models provide a powerful tool for assessing tumour growth, treatment response, and biomarker discovery. Our extensive xenograft portfolio includes models across various cancer types:
- Brain: U87MG, A172
- Breast: MCF-7, MDAMB-231, MDA-MB-453, MDA-MB-468, HCC1395, BT474
- Bladder: T24, HT-1376
- Colon: HT29, HCT116, DLD1, COLO-205
- Epidermoid: A431
- Gastric: N87
- Lung: A549, H1975, NCI-H358, NCI-H727
- Liver: HepG2, JHH7
- Kidney: ACHN
- Melanoma: A375, SK-MEL-28
- Prostate: PC3, LNCaP, VCaP, VCaP-ENZ
- Pancreas: BxPC-3, MIA PaCa-2
- Ovary: SKOV-3
- Medulloblastoma: D283
- Tongue: CAL27
Syngeneic & Immuno-Oncology (IO) Models
Syngeneic models are crucial for studying the interaction between tumours and the immune system, particularly in the development of immunotherapies. Our IO models include:
- Fibrosarcoma: MCA205, WEHI-164
- Breast Cancer: 4T1, EMT6
- Colon Cancer: CT26.WT, MC-38
- Kidney Cancer: Renca
- Lung Cancer: LL/2
- Melanoma: B16-F10
- Myeloma: J558
Humanized Mice Models
Humanized mice provide a cutting-edge platform for studying human immune responses to cancer therapies. Our models include:
- Melanoma: A-375 xenograft
Orthotopic Models (Human & Murine)
Orthotopic tumour models enable more physiologically relevant studies by implanting cancer cells into their organ-specific microenvironment. Available models:
- Colon: DLD1, HT29, HCT116, COLO-205
- Breast: MDAMB-231, 4T1, EMT6
- Pancreas: MiaPaCa2, BxPC-3
- Bladder: T24, NBT-II
- Brain: U87MG, A172
- Ovary: SKOV-3
- Liver: HepG2
- Lung: A549, H1975
- Prostate: PC3, LNCaP, VCaPc
Metastasis Models (Human & Murine)
Understanding cancer metastasis is essential for developing effective treatments. We offer metastasis models for:
- Breast: 4T1
- Lung: A549, LLC
- Melanoma: B16F10
- Fibrosarcoma: MCA 205
Angiogenesis Assay
Angiogenesis is a key process in tumour development and drug targeting. Our Matrigel plug angiogenesis assay provides insights into vascular growth in response to therapies.
Leukaemia & Lymphoma Models
We offer in vivo models for studying leukaemia and lymphoma progression and treatment:
- Acute Myeloid Leukaemia (AML): THP1, HL60
- Chronic Myelogenous Leukaemia (CML): K562
- Lymphoma: H929, U937, Raji
Disseminated Disease Models
Our disseminated models help researchers evaluate therapies for blood cancers with systemic progression:
- Leukaemia: HL-60
- Lymphoma: U-937
Why Choose Our In Vivo Disease Models?
✅ Predictive Accuracy – Our models closely replicate human disease biology, ensuring better clinical translation.
✅ Comprehensive Portfolio – Covering solid tumours, haematological malignancies, and immune-oncology applications.
✅ Customizable Solutions – Tailored study designs to meet specific research and regulatory needs.
✅ Expert Scientific Support – Our team of experts guides you at every step, from model selection to data interpretation.
Frequently Asked Questions (FAQs)
1. What are in vivo oncology and immuno-oncology models?
In vivo oncology models are living systems (such as mice) used to study how cancer grows and how new treatments affect tumours. Immuno-oncology models help researchers test therapies that work with the immune system to fight cancer.
2. What is the difference between CDX, syngeneic, and humanized mice models?
- CDX (Cell Line Derived Xenograft) Models: Use human cancer cells in mice to study tumour growth and drug response.
- Syngeneic Models: Use mouse cancer cells in mice with an intact immune system, ideal for testing immunotherapies.
- Humanized Mice Models: Mice with a human-like immune system, allowing researchers to test therapies that rely on human immune responses.
3. Why are orthotopic models important in cancer research?
Unlike standard models where tumours grow under the skin, orthotopic models place tumours in the organ they originate from (e.g., lung cancer in the lungs). This makes the study more realistic and helps predict how the cancer and treatment will behave in real patients.
4. How do metastasis models help in drug development?
These models focus on how cancer spreads (metastasis) to different organs like the lungs, liver, or bones. They are essential for developing treatments that stop the spread of cancer and improve survival rates.
5. What is an angiogenesis assay, and why is it important?
Angiogenesis is how tumours create new blood vessels to grow. The angiogenesis assay helps researchers understand how new therapies can stop this process, cutting off the tumour’s blood supply and slowing its growth.
Choosing the right in vivo pharmacology model can make all the difference in your drug development journey. Accelerate your research with proven in vivo models
Accelerate Your Oncology Research Today